Improving Fragment Based Drug Discovery and the Development of Tools for Chemical Biology through Nanoscale Encapsulation and NMR Spectroscopy

通过纳米级封装和核磁共振波谱改善基于片段的药物发现和化学生物学工具的开发

基本信息

  • 批准号:
    10707914
  • 负责人:
  • 金额:
    $ 29.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-20 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Despite tremendous technical advances in drug discovery, de novo development of small molecule drugs is still challenging. High-throughput screening (HTS) with libraries of natural products and other complex molecules remains the bedrock approach. However, HTS is unsatisfactory in many ways: extraordinary cost, poor efficiency, rampant false positives and a complexity of “hits” that hinders hit-to-lead development. Fragment based drug discovery (FBDD) was brilliantly conceived to overcome these limitations, but has arguably not performed as hoped. The limited impact of FBDD is because most fragment “hit” molecules are very weak binders and are undetectable by current assay methods. The enormous potential of FBDD is therefore lost. Here, an approach is to be developed that can reliably detect weak but specific binding with the goal of helping to reinvigorate and enhance early phase small molecule drug discovery. Faithful detection of binding requires that the ligand and protein concentrations be at least on the order of the dissociation constant, which is practically and financially unrealistic for weak binders. The strategy to remove this basic barrier is simple. The water core of the reverse micelle (RM) is used to confine a single protein molecule and fragments at high enough concentrations to overcome the unfavorable binding entropy. NMR spectroscopy then permits site-resolved detection and quantification of binding affinity at reasonable cost. The first application of RM NMR FBDD highlights its potential to greatly expand small drug discovery. A rule- of-three (Ro3) fragment screen of interleukin-1β (IL-1β) shows that 1) weak yet specific binding can be efficiently detected in a structural context; 2) achieving the required high protein and ligand concentrations is economically feasible; 3) a high hit rate is observed; 4) surface coverage is extraordinary and gives unprecedented connectivity potential; 5) highly desired more polar binders are illuminated. The door is now open to more fully realize the tremendous promise of FBDD but critical questions remain: Is the IL-1β surface coverage typical? What is the distribution of fragment hit affinities of Ro3 and rule-of-five (Ro5) libraries more generally? What are the chemical characteristics of useful fragments to choose for an optimal RM NMR screening library? How useful are the very weakly binding hits for lead development? Does the Ro5 library offer a better compromise of hit affinity and surface coverage? What is the most efficient way to carry out RM NMR screening? Is RM NMR screening quantitatively reliable? This project will address these and other technical challenges that stand in the way of creating a strategy that more fully enables the brilliant insights of the FBDD paradigm and unleashes its originally anticipated potential.
尽管在药物发现方面取得了巨大的技术进步,但小分子药物的从头开发仍然是困难的。 挑战性利用天然产物和其他复杂分子库进行高通量筛选(HTS) 仍然是基本方法。然而,HTS在许多方面都不令人满意:成本过高, 效率、猖獗的误报和阻碍“点击率领先”发展的“点击率”的复杂性。片段 基于药物发现(FBDD)的构想很好地克服了这些局限性,但可以说没有 正如所希望的那样。FBDD的有限影响是因为大多数碎片“命中”分子是非常弱的粘合剂 并且不能通过当前的分析方法检测到。因此,FBDD的巨大潜力丧失了。这里是 将开发一种方法,该方法可以可靠地检测微弱但特异性的结合,目的是帮助 重振和加强早期小分子药物的发现。 结合的可靠检测要求配体和蛋白质浓度至少为约0.5 μ mol/L。 解离常数,这对于弱粘合剂在实践上和经济上是不现实的。移除的策略 这个基本的屏障很简单。反胶束(RM)的水核用于限制单个蛋白质分子 和足够高浓度的碎片以克服不利的结合熵。NMR光谱 然后允许以合理的成本进行结合亲和力的位点分辨检测和定量。 RM NMR FBDD的首次应用突出了其极大扩展小型药物发现的潜力。一条规则- 白细胞介素-1 β(IL-1β)的三(Ro 3)片段筛选显示:1)弱但特异性结合可有效地与IL-1 β结合, 在结构背景下检测; 2)实现所需的高蛋白质和配体浓度是经济的 可行; 3)观察到高命中率; 4)表面覆盖率非常高,并提供了前所未有的连通性 潜在的; 5)高度期望的更极性的粘合剂被照亮。 现在,更充分地实现FBDD的巨大前景的大门已经打开,但关键问题仍然存在: IL-1β表面覆盖率是否典型?Ro 3和五规则(Ro 5)的碎片命中亲和力分布如何? 图书馆一般?对于一个最佳的RM,有哪些有用的碎片的化学特性可供选择 核磁共振筛选库?如何有用的是非常弱的结合命中铅发展?Ro 5库是否 提供命中亲和力和表面覆盖率的更好折衷?实施风险管理最有效的方法是什么 核磁共振筛选?RM NMR筛选定量可靠吗?该项目将解决这些和其他 技术挑战,阻碍了创建一个更充分地实现卓越洞察力的战略, FBDD范式并释放其最初预期的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A. JOSHUA WAND其他文献

A. JOSHUA WAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A. JOSHUA WAND', 18)}}的其他基金

Improving Fragment Based Drug Discovery and the Development of Tools for Chemical Biology through Nanoscale Encapsulation and NMR Spectroscopy
通过纳米级封装和核磁共振波谱改善基于片段的药物发现和化学生物学工具的开发
  • 批准号:
    10419416
  • 财政年份:
    2022
  • 资助金额:
    $ 29.84万
  • 项目类别:
The role of the free energy landscape in Parkin's function and dysfunction in health and disease
自由能景观在健康和疾病中帕金功能和功能障碍中的作用
  • 批准号:
    9883915
  • 财政年份:
    2020
  • 资助金额:
    $ 29.84万
  • 项目类别:
The role of the free energy landscape in Parkin's function and dysfunction in health and disease
自由能景观在健康和疾病中帕金功能和功能障碍中的作用
  • 批准号:
    10577825
  • 财政年份:
    2020
  • 资助金额:
    $ 29.84万
  • 项目类别:
The role of the free energy landscape in Parkin's function and dysfunction in health and disease
自由能景观在健康和疾病中帕金功能和功能障碍中的作用
  • 批准号:
    10356030
  • 财政年份:
    2020
  • 资助金额:
    $ 29.84万
  • 项目类别:
Nanoscale Encapsulation for Fragment Based Drug Discovery
用于基于片段的药物发现的纳米级封装
  • 批准号:
    9241998
  • 财政年份:
    2016
  • 资助金额:
    $ 29.84万
  • 项目类别:
Sensitivity enhancement in solution NMR through dynamic nuclear polarization
通过动态核极化提高溶液 NMR 的灵敏度
  • 批准号:
    8875018
  • 财政年份:
    2013
  • 资助金额:
    $ 29.84万
  • 项目类别:
Sensitivity enhancement in solution NMR through dynamic nuclear polarization
通过动态核极化提高溶液 NMR 的灵敏度
  • 批准号:
    8575416
  • 财政年份:
    2013
  • 资助金额:
    $ 29.84万
  • 项目类别:
Sensitivity enhancement in solution NMR through dynamic nuclear polarization
通过动态核极化提高溶液 NMR 的灵敏度
  • 批准号:
    8729503
  • 财政年份:
    2013
  • 资助金额:
    $ 29.84万
  • 项目类别:
Fluctuations and entropy in the energetics and function of protein complexes
蛋白质复合物的能量学和功能中的波动和熵
  • 批准号:
    8515476
  • 财政年份:
    2012
  • 资助金额:
    $ 29.84万
  • 项目类别:
Fluctuations and entropy in the energetics and function of protein complexes
蛋白质复合物的能量学和功能中的波动和熵
  • 批准号:
    8345729
  • 财政年份:
    2012
  • 资助金额:
    $ 29.84万
  • 项目类别:

相似海外基金

Treecle - data and automation to unlock woodland creation in the UK to achieve net zero
Treecle - 数据和自动化解锁英国林地创造以实现净零排放
  • 批准号:
    10111492
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    SME Support
STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications.
STTR 第二阶段:用于药物筛选应用的片上内皮微流体装置的优化制造和基于机器学习的自动化。
  • 批准号:
    2332121
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Cooperative Agreement
Improving access to AI automation to support new digital offerings within Professional/Financial Services
改善对人工智能自动化的访问,以支持专业/金融服务中的新数字产品
  • 批准号:
    10095096
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Collaborative R&D
Cost-Effective, AI-driven Automation Technology for Cell Culture Monitoring: Boosting Efficiency and Sustainability in Industrial Biomanufacturing and Streamlining Supply Chains
用于细胞培养监测的经济高效、人工智能驱动的自动化技术:提高工业生物制造的效率和可持续性并简化供应链
  • 批准号:
    10104748
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Launchpad
Sustainable Remanufacturing solution with increased automation and recycled content in laser and plasma based process (RESTORE)
可持续再制造解决方案,在基于激光和等离子的工艺中提高自动化程度和回收内容(RESTORE)
  • 批准号:
    10112149
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    EU-Funded
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
  • 批准号:
    10087446
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Collaborative R&D
SBIR Phase II: Radar-based Building Automation
SBIR 第二阶段:基于雷达的楼宇自动化
  • 批准号:
    2335079
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Cooperative Agreement
Automation and cost reduction of the hardware and software components of a novel indoor sustainable vertical growing solution
新型室内可持续垂直种植解决方案的硬件和软件组件的自动化和成本降低
  • 批准号:
    83007861
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Innovation Loans
Artificial intelligence coupled to automation for accelerated medicine design
人工智能与自动化相结合,加速药物设计
  • 批准号:
    EP/Z533038/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Research Grant
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 29.84万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了